Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2021 After-Hours Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2021
After-Hours earnings guidance on Tuesday morning. The company provided EPS guidance of 1.40-1.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.70. The company issued revenue guidance of $375-395 million, compared to the consensus revenue estimate of $400.15 million.

Halozyme Therapeutics stock traded down $1.48 during midday trading on Tuesday, reaching $47.21. The stock had a trading volume of 1,464,193 shares, compared to its average volume of 1,122,751. Halozyme Therapeutics has a 12 month low of $12.71 and a 12 month high of $51.30. The firm’s 50-day moving average price is $47.53 and its 200 day moving average price is $36.65. The firm has a market capitalization of $6.38 billion, a PE ratio of 268.94 and a beta of 1.77. The company has a quick ratio of 16.36, a current ratio of 18.49 and a debt-to-equity ratio of 3.98.

HALO has been the topic of a number of research reports. Berenberg Bank initiated coverage on Halozyme Therapeutics in a research note on Thursday, December 17th. They issued a buy rating and a $50.00 price objective on the stock. Smith Barney Citigroup boosted their price objective on Halozyme Therapeutics from $29.00 to $41.00 in a research note on Friday, December 11th. BMO Capital Markets boosted their price objective on Halozyme Therapeutics from $56.00 to $65.00 and gave the company an outperform rating in a research note on Monday, January 25th. Piper Sandler upped their price target on Halozyme Therapeutics from $42.00 to $50.00 and gave the company an overweight rating in a research report on Thursday, January 14th. Finally, Wells Fargo & Company upped their price target on Halozyme Therapeutics from $39.00 to $60.00 and gave the company an overweight rating in a research report on Monday, November 16th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Halozyme Therapeutics has an average rating of Buy and an average price target of $40.36.

In related news, Director Kenneth J. Kelley sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 4th. The shares were sold at an average price of $42.91, for a total value of $214,550.00. Following the transaction, the director now directly owns 195,123 shares in the company, valued at $8,372,727.93. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, December 21st. The stock was sold at an average price of $42.58, for a total transaction of $510,960.00. Following the completion of the transaction, the senior vice president now owns 123,400 shares in the company, valued at $5,254,372. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 223,376 shares of company stock worth $9,530,988. 2.60% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Story: Balanced Fund